Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

Background Everolimus is an oral mTOR-inhibitor. Preclinical data show synergistic effects of mTOR inhibition in combination with 5-fluorouracil-based anticancer therapy. The combination of everolimus with capecitabine seems therefore an attractive new, orally available, treatment regimen. Patients...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Deenen, Maarten J., Klümpen, Heinz-Josef, Richel, Dick J., Sparidans, Rolf W., Weterman, Mariette J., Beijnen, Jos H., Schellens, Jan H. M., Wilmink, Johanna W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2011
Soggetti:
Phase I Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388253/
https://ncbi.nlm.nih.gov/pubmed/21809026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9723-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi